Treatment in germ cell tumours: State of the art

European Journal of Surgical Oncology

Volumn 23, Issue 2, 1997, Pages 110-117

  Tjan Heijnen, V C G ^a,c   Oosterhof, G O N ^a   De Wit, R ^b   De Mulder, P H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Chemotherapy; Germ cell tumours; Review; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; DRUG EFFICACY; GERM CELL TUMOR; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA; TREATMENT OUTCOME;

EID: 0030943077     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)80002-9     Document Type: Article

References (77)

1. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8.
2. Fitzharris BM, Kaye SB, Saverymuttu S, et al. VP-16-213 as a single agent in advanced testicular tumors. Eur J Cancer 1980; 16: 1193-7.
3. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastin or etoposide. N Engl J Med 1987; 316: 1435-40.
4. International Germ Cell Cancer Collaborative Group. The international germ cell consensus classification: a prognostic factor-based staging system for metastic germ cell cancers. J Clin Oncol (in press).
5. Levi JA, Raghaven D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 1993; 11: 1300-5.
6. Wit R de, Stoter G, Kaye SB, et al. The importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC genito-urinary tract cancer cooperative group. J Clin Oncol 1997; in press.
7. Loehrer PJ, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995; 13: 470-6.
8. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastin + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988; 6: 1231-8.
9. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplating versus etoposide and carboplatin in patients with good-risk germ cell tumours: a Multiinstitutional Study. J Clin Oncol 1993; 11: 598-606.
10. Horwich A, Sleijfer DTh, Fossa SD, et al. A trial of carboplatin-based combination chemotherapy in good prognosis metastatic testicular non seminoma. Proc Am Soc Clin Oncol 1994: 13: 231 (abstract 709).
11. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
12. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7: 387-91.
13. Stoter G, Sleijfer DTh, Schornagel JH, et al. BEP versus VIP in intermediate risk patients with disseminated non-seminomalous testicular cancer (NSTC). Proc Am Soc Clin Oncol 1993; 12: 232.
14. Nichols CR, Loehrer PJ, Einhorn LH, et al. Phase III study of cisplatin, etoposide and bleomycin (PVP-16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumours: an intergroup trial. Proc Am Soc Clin Oncol 1995; 14: 239.
15. Bosl GJ, Geller NL, Vogelzang NJ, et al. Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 1987; 5: 436-40.
16. Logothetis CJ, Samuels ML, Selig DE, et al. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Am J Med 1986; 81: 219-28.
17. Newlands ES, Bagshawe KD, Begent RHJ, et al. Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol 1986; 58: 307-14.
18. Harstrick A, Schmoll HJ, Köhne-Wömpner CH, et al. Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol 1991; 2: 197-202.
19. Lewis CR, Fossa SD, Mead G, et al. BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991; 2: 203-11.
20. Horwich A, Dearnaley DP, Norman A, et al. Accelerated chemotherapy for poor prognosis germ cell tumours. Eur J Cancer 1994; 30A: 1607-11.
21. Wit R de, Stoter G, Sleyfer DTh, et al. Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995; 71: 1311-14.
22. Kaye SB, Mead GM, Fossa S, et al. An MRC/EORTC randomised trial in poor prognosis metastatic teratoma, comparing BEP with BOP-VIP. Proc Am Soc Clin Oncol 1995; 14: 246.
23. Samson MK, Rivkin SE, Jones SE, et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 1984; 53: 1029-35.
24. Ozols RF, Ihde DC, Marston Linehan W, et al. A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988; 6: 1031-40.
25. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-72.
26. Einhorn LH, Williams SD. Chemotherapy of disseminated testicular cancer: a random prospective study. Cancer 1980; 46: 1339-44.
27. Stoter G, Sleijfer DT, ten Bokkel Huinink WW, et al. High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of nonseminomatous testicular cancer: a randomized study of the EORTC genitourinary tract cancer cooperative group. J Clin Oncol 1986; 4: 1199-206.
28. Bokemeyer C, Schmoll HJ, Harstrick A, et al. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Eur J Cancer 1993; 29A: 2225-31.
29. Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-35.
30. Wit R de, Sylvester R, Tsitsa C, et al. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer 1997; in press.
31. Bokemeyer C, Schmoll HJ. Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). Eur Urol 1993; 23: 223-30.
32. Tjan-Heijnen VCG, Oosterhof GON, De Mulder PHM. Adjuvant chemotherapy for high risk stage 1 germ cell testis cancer. In: Abi-Aad AS (ed.) Adjuvant Treatment in Urological Cancer. Parthenon Publishing, in press.
33. Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage. A non-seminomatous germ cell testis cancer: review of the Indiana University Experience. Br J Urol 1993; 71: 326-35.
34. Sternberg CN. Role of primary chemotherapy in stage I and low-volume stage II non-seminomatous germ-cell tumors. Urol Clin N Am 1993; 20: 93-109.
35. Hoskin P, Duly S, Easton D, et al. Prognostic factors in stage I non-seminomatous germ-cell tumors managed by orchidectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986; 4: 1031-6.
36. Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987; 2: 294-8.
37. Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin N Am 1991; 18: 561-73.
38. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10: 1762-8.
39. Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council Report. J Clin Oncol 1996; 14: 1106-13.
40. Singhal S, Dixit S, Vyas RK, et al. Postorchidectomy management in stage I testicular seminoma: elective irradiation or surveillance? Aust Radiol 1993; 37: 205-9.
41. Fossa SD, Horwich A, Russell JM, et al. Optimal field size in adjuvant radiotherapy of stage I seminoma - a randomized trial. Proc Am Soc Clin Oncol 1996; 15: 239 (Abstract 595).
42. Oliver RTD, Edmonds PM, Ong JYH, et al. Pilot studies of 2 and I course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? J Radiat Oncol Biol Phys 1994; 29: 3-8.
43. Wheeler BM, Loehrer PJ, Williams SD, et al. Ifosfamide in refractory male germ cell tumors. J Clin Oncol 1986; 4: 28-34.
44. Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540-6.
45. Motzer RJ, Cooper K, Geller N L, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990; 66: 2476-81.
46. Harstrick A, Schmoll HJ, Wilke H, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 1991; 9: 1549-55.
47. Bosl GJ, Yagoda A, Golbey RB, et al. Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 1985; 78: 423-8.
48. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-83.
49. Hutter H, Motzer R, Schwartz, et al. Phase II trial of Taxol in cisplatin-resistant germ cell tumor (GCT) patients. Proc Am Soc Clin Oncol 1994; 13: 232 (abstract 712).
50. Christou A, Roth B, Fox S, et al. Phase II trial of paclitaxel in refractory germ cell neoplasms. Proc Am Soc Clin Oncol 1996; 15: 249 (abstract 632).
51. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer - A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-9.
52. Barnett M, Coppin C, Murray N, et al. Intensive therapy and autologous bone marrow transplantation (BMT) for patients with poor prognosis nonseminomatous germ cell tumors. Proc Am Soc Clin Oncol 1991; 10: 165.
53. Rosti G, Albertazzi L, Salvioni R, et al. High dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol 1992; 3: 809-12.
54. Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 1994; 12: 1223-31.
55. Broun RE, Nichols CR, Kneebone P, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-8.
56. Linkesch W, Kuhrer I, Wagner A. Rhu-GM-CSF after ultra-high dose carboplatin, VP-16, cyclophosphamide with ABMT in refractory germ cell cancer. Proc Am Soc Clin Oncol 1990; 9: 114.
57. Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumours: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996; 14: 1098-105.
58. Farhat F, Culine S, Théodore C, et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 1996; 77: 1193-7.
59. Ulbright TM, Loehrer PJ, Roth LM, et al. The development of non-germ cell malignancies within germ cell tumours. Cancer 1984; 54: 1824-33.
60. Logothetis CJ, Samuels ML, Trindace A, et al. The growing teratoma syndrome. Cancer 1982; 50: 1629-35.
61. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993; 11: 1294-9.
62. Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996; 14: 1765-9.
63. Fossa SD, Qvist H, Stenwig AE, et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992; 10: 569-73.
64. Toner G, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990; 8: 1683-94.
65. Gerl A, Clemm C, Schmeller N, et al. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 1995; 6: 483-8.
66. Steyerberg EW, Keizer HJ, Zwartendijk J, et al. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer 1993; 68: 195-200.
67. Hendry WF, A'Hern RP, Hetherington JWJ, et al. Para-aortic lymphadenectomy after chemotherapy for metastatic nonseminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 1993; 71: 208-13.
68. Steyerberg EW, Keizer HJ, Messemer JE, et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Cancer 1997; 79: 345-55.
69. Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981; 41: 3275-80.
70. Einhorn LH, Williams SD, Mandelbaum I, et al. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981; 48: 904-8.
71. Nijman JM, Schraffordt Koops H, Oldhoff J, et al. Sexual function after surgery and combination chemotherapy in men with disseminated nonseminomatous testicular cancer. J Clin Oncol 1987; 5: 651-6.
72. Wood DP, Herr HW, Motzer RJ, et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 1992; 70: 2354-7.
73. Peckham MJ, Horwich A, Hendry WF. Advanced seminoma treatment with cisplatinum based combination chemotherapy or carboplatin. Br J Cancer 1985; 52: 7-13.
74. Loehrer PJ Sr, Birch R, Williams SD, et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987; 5: 1212-20.
75. Fossa SD, Borge L, et al. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987; 5: 1071-7.
76. Motzer R, Bosl G, Heelan R, et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987; 5: 1064-70.
77. Sheinfield J, Bajorin D. Management of postchemotherapy residual mass. Urol Clin N Am 1993; 20: 133-43.